Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) News
Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP)
Today's Latest Price: $68.52 USD
Updated Dec 1 4:00pm
Add HZNP to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
Filter HZNP News Items
HZNP News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest HZNP News From Around the Web
Below are the latest news stories about Horizon Therapeutics Public Ltd Co that investors may wish to consider to help them evaluate HZNP as an investment opportunity.
Horizon Therapeutics plc Named as an Angels in Adoption® Honoree by U.S. Congressional Coalition on Adoption for #RAREis Adoption Fund partnership with Gift of AdoptionDUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) was named as a 2020 Angels in Adoption® Honoree for the company’s outstanding advocacy for adoption of children living with rare diseases. The Congressional Coalition on Adoption Institute (CCAI), which coordinates the Angels in Adoption® Program, honored Horizon at its virtual gala on Sept. 30, 2020. The company was nominated by U.S. Senator Tammy Duckworth (D-IL). Horizon was recognized for its innovative #RAREis Adoption Fund p |
The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPOScaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than... |
MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with MethotrexateDUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the complete dataset on the primary endpoint from its Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA (MIRROR) open-label trial in the Journal of Rheumatology [https://doi.org/10.3899/jrheum.200460]. Horizon’s MIRROR clinical program includes the completed multi-center, open-label trial as well as an ongoing randomized controlled trial (RCT). The tri |
Horizon Therapeutics plc Named to the 2020 PEOPLE “50 Companies That Care” ListDUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of PEOPLE’s “50 Companies That Care” for 2020. The 2020 “50 Companies That Care” list spotlights 50 U.S. companies with 1,000 or more employees and their response to taking care of their employees, their communities and the world during the COVID-19 crisis. The list will be featured in the Sept. 14, 2020 print issue of PEOPLE. “It is a special honor to be recognized by PEOPLE and Great Pl |
Horizon Therapeutics plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Ordinary SharesDUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the closing of its underwritten public offering of 13,570,000 of its ordinary shares at a price to the public of $71.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,770,000 additional ordinary shares. The net proceeds to the Company from this offering are expected to be approximately $919.3 million, after deducting underwriting discounts and other estimated o |
Horizon Therapeutics Named one of the Best Places to Work in Chicago by Crain’s Chicago BusinessDUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named to the Crain’s Chicago Business 2020 Best Places to Work in Chicago list. “It’s a tremendous honor that Crain’s Chicago Business ranked us among the Best Places to Work in Chicago where many Horizon employees live and work,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “Despite these challenging times, working at Horizon remains grounded in the strength of our c |
Bullish Signal Could Catapult Pharma Stock HigherHorizon Therapeutics stock is flashing a bull signal that could catapult it to a new record high |
Horizon Therapeutics plc Announces Pricing of Public Offering of Ordinary SharesDUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the pricing of its underwritten public offering of 11,800,000 of its ordinary shares at a price to the public of $71.00 per share. The net proceeds to the Company from this offering are expected to be approximately $798.9 million, after deducting underwriting discounts and other estimated offering expenses payable by the Company. The Company has also granted the underwriters a 30-day option to purchase up to an add |
Horizon Therapeutics Named 2020 Top Workplace for Millennials by FortuneDUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named to the 2020 Fortune Best Workplaces for Millennials™ list. Horizon ranked 7th among 25 companies in the small and medium company category in its first year on the list. “We’re proud that Fortune and Great Place to Work recognized the focus we put on developing employees at each phase of their careers, including those in the beginning stages,” said Tim Walbert, chairman, president and chief ex |
Horizon Therapeutics EPS beats by $0.04, beats on revenueHorizon Therapeutics (HZNP): Q2 Non-GAAP EPS of $0.40 beats by $0.04; GAAP EPS of -$0.42 misses by $0.41.Revenue of $462.8M (+44.4% Y/Y) beats by $129.1M.Press Release... |
